Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration

Trial Profile

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Nov 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top